Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon (RIPC-DCB)
Primary Purpose
Coronary Artery Disease
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
RIPC
Sponsored by
About this trial
This is an interventional other trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- Diameter stenosis>=50% by visual estimation intend to undergo drug-coated balloon implantation
- Target vessel diameter> 2.5mm
Exclusion Criteria:
- Chronic Total Obstructive lesion
- Diagnose patients with acute myocardial infarction <24 hours
- Can't tolerate or not suitable for RIPC
- Severe hepatic and renal insufficiency
- Expected survival <1 year
- Severe calcification needing rotational atherectomy
- Intolerable to dual antiplatelet therapy
Sites / Locations
- Fuwai central China cardiovascular HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Experimental
Control
Arm Description
40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
Outcomes
Primary Outcome Measures
TLF
TLF, a composite of cardiac death, target vessel-related myocardial infarction (MI; not clearly attributed to a nontarget vessel and excluding periprocedural MI), or clinically indicated target lesion revascularization (TLR)
Secondary Outcome Measures
Late lumen loss of target vessel(mm)
Late Lumen Loss of target vessel(mm) by Quantitative Coronary Angiography (QCA).
DCB expansion time
We hypothesis/speculated that the RIPC group had better ischemia tolerance, so the balloon dilation time was longer than the control group.
But the total time for all patients is less than 120 seconds
Full Information
NCT ID
NCT04766749
First Posted
February 10, 2021
Last Updated
August 3, 2022
Sponsor
Henan Institute of Cardiovascular Epidemiology
1. Study Identification
Unique Protocol Identification Number
NCT04766749
Brief Title
Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon
Acronym
RIPC-DCB
Official Title
Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 24, 2021 (Actual)
Primary Completion Date
February 20, 2023 (Anticipated)
Study Completion Date
February 20, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Henan Institute of Cardiovascular Epidemiology
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Drug-coated balloon is being used more and more widely for the advantage of intervention without implantation.
But the balloon needs to be released long enough to be effective. Prolonged balloon dilation resulting in the cessation of blood flow in the distal vessels, especially large vessels, may result in severe ischemia in the patient.
RIPC can enhance patients' tolerance to ischemic events, so we believe that RIPC application before the use of drug balloon for PCI can improve patients' ischemic symptoms, thus increasing the release time of drug balloon and improving the effect.
Detailed Description
Some patients receiving PCI cannot tolerate the symptoms of myocardial ischemia caused by the release of the drug balloon for a long time and even lead to the occurrence of adverse events.RIPC was found to improve tolerance to myocardial ischemia in patients.
At the same time, it can open collateral circulation and improve the tolerance of myocardial ischemia in patients.Therefore, this study designed a parallel control group. The experimental group was treated with RIPC before PCI, while the control group was not treated before PCI.
The operator does not know whether the patient has undergone RIPC or not, and the operator decides the time of drug balloon release according to the symptoms of the patient during the operation.Angiography was performed at 6 months, and QCA was used to determine late lumen loss at 1 year.The 1-year incidence of target lesion failure events was assessed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Before the operation, the nurse chooses the patient to perform RIPC or not according to a predefined random method, and then the operation is performed by the operator.
The operator did not know if the patient had undergone RIPC. Outcome evaluators also did not know the grouping of patients
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental
Arm Type
Experimental
Arm Description
40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
Arm Title
Control
Arm Type
No Intervention
Arm Description
A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
Intervention Type
Other
Intervention Name(s)
RIPC
Intervention Description
RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
Primary Outcome Measure Information:
Title
TLF
Description
TLF, a composite of cardiac death, target vessel-related myocardial infarction (MI; not clearly attributed to a nontarget vessel and excluding periprocedural MI), or clinically indicated target lesion revascularization (TLR)
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Late lumen loss of target vessel(mm)
Description
Late Lumen Loss of target vessel(mm) by Quantitative Coronary Angiography (QCA).
Time Frame
6 months
Title
DCB expansion time
Description
We hypothesis/speculated that the RIPC group had better ischemia tolerance, so the balloon dilation time was longer than the control group.
But the total time for all patients is less than 120 seconds
Time Frame
less than 120 seconds (On the 1 day of PCI)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diameter stenosis>=50% by visual estimation intend to undergo drug-coated balloon implantation
Target vessel diameter> 2.5mm
Exclusion Criteria:
Chronic Total Obstructive lesion
Diagnose patients with acute myocardial infarction <24 hours
Can't tolerate or not suitable for RIPC
Severe hepatic and renal insufficiency
Expected survival <1 year
Severe calcification needing rotational atherectomy
Intolerable to dual antiplatelet therapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Quan Guo, MD
Phone
+8615670510031
Email
xinyiguoquan@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muwei Li, MD
Organizational Affiliation
Fuwai Central China Cardiovascular Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Fuwai central China cardiovascular Hospital
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Quan Guo, MD
Phone
+8615670510031
Email
xinyiguoquan@163.com
First Name & Middle Initial & Last Name & Degree
Quan Guo, MD
First Name & Middle Initial & Last Name & Degree
Muwei Li, MD
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
After the results are published, researchers can obtain IPD from the responsible person on reasonable request
Learn more about this trial
Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon
We'll reach out to this number within 24 hrs